MINK THERAPEUTICS INC (INKT) Stock Price, Quote, News and Overview
NASDAQ:INKT - Nasdaq - US6036932019 - Common Stock - Currency: USD
INKT Quote, Performance and Key Statistics
23.25
+0.14 (+0.61%)
The current stock price of INKT is 23.25 USD. In the past month the price increased by 210.41%. In the past year, price increased by 164.21%.
INKT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.64 | 338.09B | ||
| AMGN | AMGEN INC | 14.37 | 160.37B | ||
| GILD | GILEAD SCIENCES INC | 14.06 | 135.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.41 | 59.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.34B | ||
| ARGX | ARGENX SE - ADR | 99.6 | 34.97B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.69B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.52B | ||
| INSM | INSMED INC | N/A | 19.76B | ||
| NTRA | NATERA INC | N/A | 19.58B |
Related stock screener links
About INKT
Company Profile
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The company is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Company Info
MINK THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK US
Employees: 23
Phone: 12129948250
MINK THERAPEUTICS INC / INKT FAQ
What is the stock price of MINK THERAPEUTICS INC today?
The current stock price of INKT is 23.25 USD. The price increased by 0.61% in the last trading session.
What is the ticker symbol for MINK THERAPEUTICS INC stock?
The exchange symbol of MINK THERAPEUTICS INC is INKT and it is listed on the Nasdaq exchange.
On which exchange is INKT stock listed?
INKT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MINK THERAPEUTICS INC stock?
9 analysts have analysed INKT and the average price target is 35.7 USD. This implies a price increase of 53.55% is expected in the next year compared to the current price of 23.25. Check the MINK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MINK THERAPEUTICS INC worth?
MINK THERAPEUTICS INC (INKT) has a market capitalization of 92.77M USD. This makes INKT a Micro Cap stock.
How many employees does MINK THERAPEUTICS INC have?
MINK THERAPEUTICS INC (INKT) currently has 23 employees.
Should I buy MINK THERAPEUTICS INC (INKT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INKT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INKT, evaluating the profitability, health, valuation and growth aspects
- MINK THERAPEUTICS INC (INKT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MINK THERAPEUTICS INC (INKT) Sales and EPS estimates to see what analysts future expectations are.
- MINK THERAPEUTICS INC (INKT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MINK THERAPEUTICS INC (INKT) Insider and Institutional Ownership to learn about the owners and their transactions.
- MINK THERAPEUTICS INC (INKT) Stock Chart to make your own analysis
- MINK THERAPEUTICS INC (INKT) Latest news and press-releases to stay up to date.
Does MINK THERAPEUTICS INC (INKT) stock pay dividends?
INKT does not pay a dividend.
When does MINK THERAPEUTICS INC (INKT) report earnings?
MINK THERAPEUTICS INC (INKT) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of MINK THERAPEUTICS INC (INKT)?
MINK THERAPEUTICS INC (INKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.52).
What is the Short Interest ratio of MINK THERAPEUTICS INC (INKT) stock?
The outstanding short interest for MINK THERAPEUTICS INC (INKT) is 1.26% of its float. Check the ownership tab for more information on the INKT short interest.
INKT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to INKT. When comparing the yearly performance of all stocks, INKT is one of the better performing stocks in the market, outperforming 98.49% of all stocks.
INKT Financial Highlights
Over the last trailing twelve months INKT reported a non-GAAP Earnings per Share(EPS) of -2.52. The EPS increased by 58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -228.21% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
INKT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to INKT. The Buy consensus is the average rating of analysts ratings from 9 analysts.